Article info

PDF
The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review

Authors

  1. Correspondence to Dr Carol Dryden, Department of Paediatrics, Wishaw General Hospital, Netherton Street, Wishaw ML2 0DP, UK; carol.dryden{at}lanarkshire.scot.nhs.uk
View Full Text

Citation

Dryden C, Wilkinson J, Young D on behalf of the Scottish Paediatric Cystic Fibrosis Managed Clinical Network (SPCFMCN), et al
The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review

Publication history

  • Received 29 December 2015
  • Revised 13 May 2016
  • Accepted 16 May 2016
  • Published online 10 June 2016.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.